Format

Send to

Choose Destination
Transfus Apher Sci. 2015 Dec;53(3):256-61. doi: 10.1016/j.transci.2015.11.004. Epub 2015 Nov 25.

Therapeutic apheresis in pregnancy: General considerations and current practice.

Author information

1
Apheresis Unit, Blood Transfusion Service, University Hospital of Padua, Padua, Italy. Electronic address: piero.marson@sanita.padova.it.
2
Obstetrics and Gynecology Unit, Department for Health of Woman and Child, University Hospital of Padua, Padua, Italy.
3
Apheresis Unit, Blood Transfusion Service, University Hospital of Padua, Padua, Italy.

Abstract

It is widely known that pregnancy does not represent a contraindication to therapeutic apheresis (TA) techniques. In fact, since the first experiences of TA in pregnancy for the prevention of hemolytic disease of the newborn, several diseases are at present treated with TA, mainly within 6 clinical categories: (a) TA is a priority and has no alternative equally effective treatment (e.g., thrombotic thrombocytopenic purpura); (b) TA is a priority but there are alternative therapies not contraindicated in pregnancy (e.g., myasthenia gravis); (c) TA is an effective tool of saving/avoiding drugs contraindicated in pregnancy (e.g., systemic lupus erythematosus); (d) TA is a treatment of specific conditions/complications of pregnancy with maternal and/or fetal risk (e.g., antiphospholipid syndrome); (e) TA is a treatment of specific conditions of pregnancy with exclusive fetal risk (e.g., hemolytic disease of the newborn); (f) TA is a treatment of disease which is strongly indicated and can exceptionally occur during pregnancy (e.g., Goodpasture's syndrome). When dealing with TA pregnant patients, some technical aspects due to the physiological changes of gestation have to be carefully considered, in particular the increase of the circulating blood volume. Moreover a multidisciplinary medical team, including an obstetrician, a clinical consultant, specialist in TA and in transfusion medicine, and a neonatologist stand as a basic requirement for the proper management of some clinical conditions that may be characterized by high maternal and fetal risk.

KEYWORDS:

ASFA guidelines; Hemolytic disease of the newborn; Pregnancy; Therapeutic apheresis

PMID:
26621537
DOI:
10.1016/j.transci.2015.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center